^
EGFR E746_S752delinsV
Lung Non-Small Cell Squamous Cancer
gefitinib
Sensitive: C4 – Case Studies
Dovepress - 5 weeks
EGFR expression
Lung Non-Small Cell Squamous Cancer
necitumumab
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
afatinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
tislelizumab
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
sintilimab
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
nivolumab
Sensitive: A2 - Guideline
No biomarker
Lung Non-Small Cell Squamous Cancer
bevacizumab
Resistant: A2 - Guideline
PD-L1 expression
Lung Non-Small Cell Squamous Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
No biomarker
Lung Non-Small Cell Squamous Cancer
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Lung Non-Small Cell Squamous Cancer
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Lung Non-Small Cell Squamous Cancer
docetaxel
Sensitive: A2 - Guideline
No biomarker
Lung Non-Small Cell Squamous Cancer
carboplatin + albumin-bound paclitaxel
Sensitive: A2 - Guideline
No biomarker
Lung Non-Small Cell Squamous Cancer
albumin-bound paclitaxel
Sensitive: A2 - Guideline
No biomarker
Lung Non-Small Cell Squamous Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
No biomarker
Lung Non-Small Cell Squamous Cancer
EP
Sensitive: A2 - Guideline
No biomarker
Lung Non-Small Cell Squamous Cancer
GC
Sensitive: A2 - Guideline
No biomarker
Lung Non-Small Cell Squamous Cancer
CP
Sensitive: A2 - Guideline
No biomarker
Lung Non-Small Cell Squamous Cancer
CaT
Sensitive: A2 - Guideline
No biomarker
Lung Non-Small Cell Squamous Cancer
GD
Sensitive: A2 - Guideline
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
atezolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: A2 - Guideline
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: A2 - Guideline
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
cemiplimab
Sensitive: A2 - Guideline
No biomarker
Lung Non-Small Cell Squamous Cancer
carboplatin + docetaxel
Sensitive: A2 - Guideline
No biomarker
Lung Non-Small Cell Squamous Cancer
GemVin
Sensitive: A2 - Guideline
No biomarker
Lung Non-Small Cell Squamous Cancer
ramucirumab
Sensitive: A2 - Guideline
No biomarker
Lung Non-Small Cell Squamous Cancer
atezolizumab
Sensitive: A2 - Guideline
No biomarker
Lung Non-Small Cell Squamous Cancer
VC
Sensitive: A2 - Guideline
No biomarker
Lung Non-Small Cell Squamous Cancer
GemCarbo
Sensitive: A2 - Guideline
No biomarker
Lung Non-Small Cell Squamous Cancer
DP
Sensitive: A2 - Guideline
EGFR mutation
Lung Non-Small Cell Squamous Cancer
bevacizumab
Sensitive: B - Late Trials
EGFR L858R
Lung Non-Small Cell Squamous Cancer
erlotinib
Sensitive: B - Late Trials
EGFR exon 20 insertion
Lung Non-Small Cell Squamous Cancer
EGFR inhibitor
Sensitive: B - Late Trials
EGFR exon 19 deletion
Lung Non-Small Cell Squamous Cancer
EGFR inhibitor
Sensitive: B - Late Trials
EGFR L861Q
Lung Non-Small Cell Squamous Cancer
EGFR inhibitor
Sensitive: B - Late Trials
EGFR L858R
Lung Non-Small Cell Squamous Cancer
EGFR inhibitor
Sensitive: B - Late Trials
ERBB4 G668V
Lung Non-Small Cell Squamous Cancer
afatinib
Sensitive: B - Late Trials
EGFR R1052K
Lung Non-Small Cell Squamous Cancer
afatinib
Sensitive: B - Late Trials
HER-2 E395K
Lung Non-Small Cell Squamous Cancer
afatinib
Sensitive: B - Late Trials
HER-2 Q57R
Lung Non-Small Cell Squamous Cancer
afatinib
Sensitive: B - Late Trials
High 18-gene tumor inflammation signature score
Lung Non-Small Cell Squamous Cancer
tislelizumab
Sensitive: B - Late Trials
ALK positive
Lung Non-Small Cell Squamous Cancer
brigatinib
Sensitive: C1 - Off-label
FGFR1 amplification
Lung Non-Small Cell Squamous Cancer
infigratinib
Sensitive: C2 – Inclusion Criteria
KEAP1 mutation
Lung Non-Small Cell Squamous Cancer
TAK-228
Sensitive: C2 – Inclusion Criteria
NFE2L2 mutation
Lung Non-Small Cell Squamous Cancer
TAK-228
Sensitive: C2 – Inclusion Criteria
ACSL3 overexpression
Lung Non-Small Cell Squamous Cancer
ezetimibe/simvastatin
Sensitive: C3 – Early Trials
PD-L1 expression
Lung Non-Small Cell Squamous Cancer
pembrolizumab + MK-1308
Sensitive: C3 – Early Trials
MET positive
Lung Non-Small Cell Squamous Cancer
erlotinib + ABBV-399
Sensitive: C3 – Early Trials
EGFR mutation
Lung Non-Small Cell Squamous Cancer
erlotinib + ABBV-399
Sensitive: C3 – Early Trials
PD-L1 expression
Lung Non-Small Cell Squamous Cancer
rivoceranib + camrelizumab
Sensitive: C3 – Early Trials
NFE2L2 E79K
Lung Non-Small Cell Squamous Cancer
TAK-228
Sensitive: C3 – Early Trials
PIK3CA mutation
Lung Non-Small Cell Squamous Cancer
GDC-0032
Sensitive: C3 – Early Trials
CCND1 amplification
Lung Non-Small Cell Squamous Cancer
palbociclib
Sensitive: C3 – Early Trials
FGFR1 amplification
Lung Non-Small Cell Squamous Cancer
TKI258
Sensitive: C3 – Early Trials
ALK rearrangement
Lung Non-Small Cell Squamous Cancer
ALK inhibitor
Sensitive: C3 – Early Trials
FGFR3 overexpression
Lung Non-Small Cell Squamous Cancer
BAY1163877
Resistant: C3 – Early Trials
FGFR2 overexpression
Lung Non-Small Cell Squamous Cancer
BAY1163877
Resistant: C3 – Early Trials
FGFR1 overexpression
Lung Non-Small Cell Squamous Cancer
BAY1163877
Resistant: C3 – Early Trials
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
Immunotherapy
Sensitive: C3 – Early Trials
EGFR mutation + CREBBP mutation
Lung Non-Small Cell Squamous Cancer
EGFR inhibitor + Tyrosine kinase inhibitor
Resistant: C3 – Early Trials
EGFR mutation + ZNF217 mutation
Lung Non-Small Cell Squamous Cancer
EGFR inhibitor + Tyrosine kinase inhibitor
Resistant: C3 – Early Trials
EGFR mutation + GRM8 mutation
Lung Non-Small Cell Squamous Cancer
EGFR inhibitor + Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
PIK3CA mutation + PTEN deletion
Lung Non-Small Cell Squamous Cancer
osimertinib
Sensitive: C4 – Case Studies
DDR2 S768R
Lung Non-Small Cell Squamous Cancer
dasatinib + erlotinib
Sensitive: C4 – Case Studies
STK11 mutation
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Resistant: C4 – Case Studies
MET exon 14 mutation + EGFR exon 20 insertion
Lung Non-Small Cell Squamous Cancer
afatinib
Resistant: C4 – Case Studies
MET exon 14 mutation + EGFR exon 20 insertion
Lung Non-Small Cell Squamous Cancer
anlotinib
Resistant: C4 – Case Studies
EML4-ALK fusion
Lung Non-Small Cell Squamous Cancer
brigatinib
Sensitive: C4 – Case Studies
EML4-ALK fusion + ALK G1202R
Lung Non-Small Cell Squamous Cancer
lorlatinib
Sensitive: C4 – Case Studies
EGFR L858R + T790M
Lung Non-Small Cell Squamous Cancer
gefitinib
Resistant: C4 – Case Studies
EML4-ALK fusion
Lung Non-Small Cell Squamous Cancer
alectinib
Sensitive: C4 – Case Studies
FGFR1 amplification
Lung Non-Small Cell Squamous Cancer
ABSK-091
Sensitive: D – Preclinical
FGFR1 overexpression
Lung Non-Small Cell Squamous Cancer
PRN1371
Sensitive: D – Preclinical
KL overexpression
Lung Non-Small Cell Squamous Cancer
pemetrexed
Sensitive: D – Preclinical